125500-53-0

Upstream product

• 125500-52-9 3-butyryl-4-chloro-6-(benzoyloxymethyl)-quinoline 
• 95-53-4 o-toluidine 
• 3249-68-1 ethyl butyroyl acetate 
• 125500-50-7 Benzoic acid 4-((Z)-2-ethoxycarbonyl-3-oxo-hex-1-enylamino)-benzyl ester 
• 125500-51-8 3-butyryl-6-(benzoyloxymethyl)-4(1H)-quinolone 
• 125500-49-4 2-[1-(4-Hydroxymethyl-phenylamino)-meth-(Z)-ylidene]-3-oxo-hexanoic acid ethyl ester 
• 125500-84-7 ethyl 2-(ethoxymethylene)-3-oxohexanoate 

Relevant academic research and scientific papers

Reversible inhibitors of the gastric (H+/K+)-ATPase. 4. Identification of an inhibitor with an intermediate duration of action

3-Acyl-4-(arylamino)quinolines were previously identified as gastric (H+/K+)-ATPase inhibitors, and clinical efficacy has been demonstrated for compound 3 (SK and F 96067). In the present study the further structure- activity relatio

Compounds substituted quinoline derivatives

Substituted 4-aminoquinazoline derivatives which are inhibitors of gastric acid secretion. A compound of the invention are the salts of strong acids of 3-butyryl-4-(2-methylphenylamino)-8-(hydroxymethyl)quinoline.